Search

Home > Diabetes Knowledge into Practice Podcast > SGLT2 inhibitors in review: latest data & their wider context


	Podcast:		Diabetes Knowledge into Practice Podcast
	Episode:		SGLT2 inhibitors in review: latest data & their wider context
	Category:		Health
	Duration:		00:14:03
	Publish Date:		2020-07-07 04:00:00
	Description:		The recent results of VERTIS-CV have provided new insights into the individual and class effects of SGLT2 inhibitors, prompting further considerations of the multifactorial effects of these medications. But what made this trial so thought-provoking? This week, join us for a retrospective review of outcomes trials for SGLT2 inhibitors and a detailed discussion of the VERTIS-CV trial with Dr Chris Cannon, cardiologist at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and principal investigator for the VERTIS-CV trial. References Zinman B, et al. N Engl J Med 2015; 373:2117-2128 Reiger EE, et al. Clin Diabetes. 2016; 34(4): 173–180. Perkovic V, et al. N Engl J Med 2019; 380:2295-2306 McMurray JJV, et al. N Engl J Med 2019; 381:1995-2008 Buse JB,e t al. Diabetes Care 2019 Dec; dci190066. Cannon CP, et al. Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS CV). Presented at: 80th ADA Scientific Sessions; June 16, 2020. Symposium. This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.
	Total Play:		0